Population
Cardiomyocytes in vitro and STZ-induced diabetic rat ventricles in vivo
Comparison
High glucose exposure and Nrf2 knockdown via siRNA vs Control conditions (implied)
Design
Preclinical
Authors
Loading...
HG-Nrf2 activation in hyperglycemia may inform diabetic cardiomyopathy mechanisms; leaves therapeutic targeting open pending in vivo data.
High glucose induces protective Nrf2 activation in cardiomyocytes via PKCα/PKCδ-ROS-JNK/p38 signaling, suggesting a potential therapeutic target for diabetic cardiomyopathy.
Tsai et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: